kos pharmaceuticals inc deutsche bank 31st annual healthcare conference boston may 3 2006 safe harbor this presentation contains forward looking statements that are intended to fall within the provisions under private securities litigation reform act several factors could cause actual events differ materially from including those listed in information certain cautionary section of company s report on form 10 k filed with sec for year ending dec 31 2005 and identified other reports delivering value many levels 146 227 321 441 67 108 116 103 22 27 68 70 0 75 150 225 300 375 450 525 600 675 750 2000 2001 2002 2003 2004 i n m illio teveten hct cardizem la azmacort advicor niaspan 497 752 294 173 84 55 rapid & sustained financial growth includes international sales royalty licensing revenue 69 51 53 106 9 14 15 59 2 73 1 01 05 45 95
